tetano
Editor, Senior Moderator
J Virol
. 2024 Feb 2:e0112923.
doi: 10.1128/jvi.01129-23. Online ahead of print. Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses
Han Li[SUP] #[/SUP][SUP] 1 [/SUP], Haoran Sun[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Mengyan Tao[SUP] 1 [/SUP], Qiqi Han[SUP] 1 [/SUP], Haili Yu[SUP] 1 [/SUP], Jiaqi Li[SUP] 1 [/SUP], Xue Lu[SUP] 1 [/SUP], Qi Tong[SUP] 1 [/SUP], Juan Pu[SUP] 1 [/SUP], Yipeng Sun[SUP] 1 [/SUP], Litao Liu[SUP] 1 [/SUP], Jinhua Liu[SUP] 1 [/SUP], Honglei Sun[SUP] 1 [/SUP]
Affiliations
The global circulation of clade 2.3.4.4b H5Ny highly pathogenic avian influenza viruses (HPAIVs) in poultry and wild birds, increasing mammal infections, continues to pose a public health threat and may even form a pandemic. An efficacious vaccine against H5Ny HPAIVs is crucial for emergency use and pandemic preparedness. In this study, we developed a parainfluenza virus 5 (PIV5)-based vaccine candidate expressing hemagglutinin (HA) protein of clade 2.3.4.4b H5 HPAIV, termed rPIV5-H5, and evaluated its safety and efficacy in mice and ferrets. Our results demonstrated that intranasal immunization with a single dose of rPIV5-H5 could stimulate H5-specific antibody responses, moreover, a prime-boost regimen using rPIV5-H5 stimulated robust humoral, cellular, and mucosal immune responses in mice. Challenge study showed that rPIV5-H5 prime-boost regimen provided sterile immunity against lethal clade 2.3.4.4b H5N1 virus infection in mice and ferrets. Notably, rPIV5-H5 prime-boost regimen provided protection in mice against challenge with lethal doses of heterologous clades 2.2, 2.3.2, and 2.3.4 H5N1, and clade 2.3.4.4h H5N6 viruses. These results revealed that rPIV5-H5 can elicit protective immunity against a diverse clade of highly pathogenic H5Ny virus infection in mammals, highlighting the potential of rPIV5-H5 as a pan-H5 influenza vaccine candidate for emergency use.IMPORTANCEClade 2.3.4.4b H5Ny highly pathogenic avian influenza viruses (HPAIVs) have been widely circulating in wild birds and domestic poultry all over the world, leading to infections in mammals, including humans. Here, we developed a recombinant PIV5-vectored vaccine candidate expressing the HA protein of clade 2.3.4.4b H5 virus. Intranasal immunization with rPIV5-H5 in mice induced airway mucosal IgA responses, high levels of antibodies, and robust T-cell responses. Importantly, rPIV5-H5 conferred complete protection in mice and ferrets against clade 2.3.4.4b H5N1 virus challenge, the protective immunity was extended against heterologous H5Ny viruses. Taken together, our data demonstrate that rPIV5-H5 is a promising vaccine candidate against diverse H5Ny influenza viruses in mammals.
Keywords: broad protection; clade 2.3.4.4b H5Ny viruses; highly pathogenic avian influenza viruses; intranasal immunization; parainfluenza virus 5.
. 2024 Feb 2:e0112923.
doi: 10.1128/jvi.01129-23. Online ahead of print. Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses
Han Li[SUP] #[/SUP][SUP] 1 [/SUP], Haoran Sun[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Mengyan Tao[SUP] 1 [/SUP], Qiqi Han[SUP] 1 [/SUP], Haili Yu[SUP] 1 [/SUP], Jiaqi Li[SUP] 1 [/SUP], Xue Lu[SUP] 1 [/SUP], Qi Tong[SUP] 1 [/SUP], Juan Pu[SUP] 1 [/SUP], Yipeng Sun[SUP] 1 [/SUP], Litao Liu[SUP] 1 [/SUP], Jinhua Liu[SUP] 1 [/SUP], Honglei Sun[SUP] 1 [/SUP]
Affiliations
- PMID: 38305155
- DOI: 10.1128/jvi.01129-23
The global circulation of clade 2.3.4.4b H5Ny highly pathogenic avian influenza viruses (HPAIVs) in poultry and wild birds, increasing mammal infections, continues to pose a public health threat and may even form a pandemic. An efficacious vaccine against H5Ny HPAIVs is crucial for emergency use and pandemic preparedness. In this study, we developed a parainfluenza virus 5 (PIV5)-based vaccine candidate expressing hemagglutinin (HA) protein of clade 2.3.4.4b H5 HPAIV, termed rPIV5-H5, and evaluated its safety and efficacy in mice and ferrets. Our results demonstrated that intranasal immunization with a single dose of rPIV5-H5 could stimulate H5-specific antibody responses, moreover, a prime-boost regimen using rPIV5-H5 stimulated robust humoral, cellular, and mucosal immune responses in mice. Challenge study showed that rPIV5-H5 prime-boost regimen provided sterile immunity against lethal clade 2.3.4.4b H5N1 virus infection in mice and ferrets. Notably, rPIV5-H5 prime-boost regimen provided protection in mice against challenge with lethal doses of heterologous clades 2.2, 2.3.2, and 2.3.4 H5N1, and clade 2.3.4.4h H5N6 viruses. These results revealed that rPIV5-H5 can elicit protective immunity against a diverse clade of highly pathogenic H5Ny virus infection in mammals, highlighting the potential of rPIV5-H5 as a pan-H5 influenza vaccine candidate for emergency use.IMPORTANCEClade 2.3.4.4b H5Ny highly pathogenic avian influenza viruses (HPAIVs) have been widely circulating in wild birds and domestic poultry all over the world, leading to infections in mammals, including humans. Here, we developed a recombinant PIV5-vectored vaccine candidate expressing the HA protein of clade 2.3.4.4b H5 virus. Intranasal immunization with rPIV5-H5 in mice induced airway mucosal IgA responses, high levels of antibodies, and robust T-cell responses. Importantly, rPIV5-H5 conferred complete protection in mice and ferrets against clade 2.3.4.4b H5N1 virus challenge, the protective immunity was extended against heterologous H5Ny viruses. Taken together, our data demonstrate that rPIV5-H5 is a promising vaccine candidate against diverse H5Ny influenza viruses in mammals.
Keywords: broad protection; clade 2.3.4.4b H5Ny viruses; highly pathogenic avian influenza viruses; intranasal immunization; parainfluenza virus 5.